WO2015154637A1 - Method for preparing silodosin intermediate - Google Patents

Method for preparing silodosin intermediate Download PDF

Info

Publication number
WO2015154637A1
WO2015154637A1 PCT/CN2015/075757 CN2015075757W WO2015154637A1 WO 2015154637 A1 WO2015154637 A1 WO 2015154637A1 CN 2015075757 W CN2015075757 W CN 2015075757W WO 2015154637 A1 WO2015154637 A1 WO 2015154637A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
palladium
group
bis
Prior art date
Application number
PCT/CN2015/075757
Other languages
French (fr)
Chinese (zh)
Inventor
刘琦
严加浩
徐爽
靳灿辉
谭玉东
孙仲猛
曹林法
Original Assignee
江苏和成新材料有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏和成新材料有限公司 filed Critical 江苏和成新材料有限公司
Publication of WO2015154637A1 publication Critical patent/WO2015154637A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Definitions

  • the invention belongs to the technical field of medicine, and in particular relates to a method for preparing an intermediate of silodosin and a novel intermediate compound involved in the method.
  • Benign prostatic hyperplasia is a common and frequently-occurring disease in middle-aged and elderly men.
  • drugs used to treat BPH are mainly divided into two categories: ⁇ 1 adrenergic receptor ( ⁇ -AR) antagonist and 5 ⁇ reductase inhibitor.
  • ⁇ -AR antagonists are characterized by fast, safe and efficient.
  • Silodosin is an alpha-AR antagonist of BPH for the treatment of dysuria caused by benign prostatic hyperplasia.
  • Silodosin has a selective inhibitory effect on urethral smooth muscle contraction, and reduces intraurethral pressure, but has no significant effect on blood pressure, and has few side effects, and thus can be used for treating benign prostatic hyperplasia.
  • synthetic methods for silodosin there are many synthetic methods for silodosin, but there is a lack of a simple process, high yield, and suitable for industrial large-scale production.
  • optically active R-compound of formula M below is a key intermediate in the preparation of silodosin.
  • Asymmetric reductive amination with L-phenylglycinol gives the desired product.
  • the method uses L-phenylglycinol, reductive amination to obtain a mixture of diastereomers of the following formula III (diastereomer ratio 3.8:1),
  • sirolimus As a key intermediate for the preparation of silodosin, a compound of the formula M has been used to prepare sirolimus which has been reported in JP2001199956, JP2006188470, WO2011124704.
  • the present invention has been proposed in the synthesis of silodosin based on the prior art, since the preparation of the key intermediate, optically active compound M, generally complicates the synthesis process and is costly.
  • the method can improve the industrial production feasibility of synthesizing the compound, reducing the risk and cost.
  • One aspect of the present invention provides a method for preparing a compound of Formula M, which in turn comprises the following five steps:
  • the method specifically includes the following steps:
  • An organozinc reagent is prepared by reacting with zinc powder, and the organozinc reagent is reacted with a compound of formula 5 under the catalysis of a palladium catalyst and an organic ligand to obtain a compound of formula 7
  • R represents a benzyl group or a benzoyl group.
  • the steps 1) to 5) are each carried out in an organic solvent, and the organic solvents in the steps 1) to 5) are each independently selected from the group consisting of C 1 -C 4 lower alcohols, toluene, and A group consisting of toluene, glacial acetic acid, dichloromethane, 1,2-dichloroethane, dimethyl sulfoxide, trifluoroacetic acid, ethyl acetate, N,N-dimethylformamide, and combinations thereof.
  • the alkaline agent in step 1) is selected from the group consisting of sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, potassium iodide, sodium hydrogencarbonate, diisopropylethylenediamine, pyridine, choline.
  • the palladium catalyst in step 4) is selected from the group consisting of palladium acetate, tetrakis(triphenylphosphine)palladium, palladium chloride, [1,1'-bis(diphenylphosphine) dioxin Iron] palladium dichloride, 1,1'-bis(diphenylphosphino)ferrocene palladium (II) dichloride Methyl chloride complex, bis(tricyclohexylphosphine)palladium dichloride, bis(triphenylphosphine)palladium(II) dichloride, bis(dibenzylideneacetone)palladium(0), tris(dibenzylidene) Acetone) dipalladium chloroform adduct, di(acetylacetonate)palladium(II), palladium hydroxide carbon, palladium carbon, (1,5-cyclooctadiene) palladium dichloride
  • the organic ligand in step 4) is selected from the group consisting of triphenylphosphine, tricyclohexylphosphine, diphenylcyclohexylphosphine, 4,5-bisdiphenylphosphine-9,9 - dimethylxanthene, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, Di-tert-butylcyclohexylphosphine, tri(o-tolyl)phosphine, 2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl, 1,2,3,4,5 -pentaphenyl-1'-(di-tert-butylphosphine)ferrocene, 1,1'-bis(diphenyl)
  • the acidic condition in step 5) is obtained by adding an acid or a hydrogen chloride gas, wherein the acid is selected from the group consisting of concentrated hydrochloric acid, trifluoroacetic acid, acetic acid or formic acid, wherein the concentrated hydrochloric acid is a volume concentration. It is 37% hydrochloric acid.
  • the palladium catalyst in the step 4) is selected from the group consisting of palladium acetate, bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium chloroform adduct or di(acetyl). Acetone) Palladium (II).
  • the palladium catalyst in the step 4) is bis(acetylacetonate)palladium(II).
  • the organic ligand in the step 4) is selected from the group consisting of tri-tert-butylphosphine, 2-dicyclohexylphosphine-2', 4',6'-triisopropylbiphenyl, 2-bicyclic ring Hexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl, 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphine)ferrocene Or 4,5-bisdiphenylphosphino-9,9-dimethyloxazepine.
  • the organic ligand in the step 4) is 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphine)ferrocene.
  • the reaction temperature of the step 1), the step 2) and the step 3) is 50 to 200 ° C
  • the reaction time is 1 to 10 h
  • the reaction temperature is 60 to 150 ° C
  • the reaction time is It is 3 to 8 hours.
  • the reaction temperature of the step 4) and the step 5) is -20 to 50 ° C
  • the reaction time is 1 to 10 h, preferably the reaction temperature is -10 to 30 ° C, and the reaction time is 1 to 5 h. .
  • One aspect of the present invention provides novel intermediate compounds involved in the above preparation methods:
  • One aspect of the present invention provides a method of preparing a compound of Formula 6, comprising the steps of:
  • the method specifically includes the following steps:
  • a compound represented by the formula SLD-9C is reacted with thionyl chloride for 3 to 10 hours under an organic solvent-containing reflux condition to obtain a compound represented by the formula SLD-8C.
  • reaction conditions include the aforementioned reaction of the compound of the formula M. Conditions are not the only way to implement the technical solution of the present invention. Those skilled in the art can implement the technical solution of the present invention by modifying the reaction conditions according to actual needs without departing from the gist of the present invention.
  • An advantage of the present invention is that the compound of formula M synthesized by the process of the invention can be used as an intermediate compound for the synthesis of sirolimus. This method has the following advantages:
  • reaction conditions are mild, and the operation is simple and suitable for industrial production.
  • Figure 1 is a 1 H NMR chart of the compound SLD-8C
  • Figure 2 is a 1 H NMR chart of the compound SLD-7C
  • Figure 3 is a 1 H NMR chart of the compound SLD-6C
  • Figure 4 is a 1 H NMR chart of Compound 6
  • FIG. 5 is a MS diagram of Compound 3-1
  • Figure 6 is a MS diagram of Compound 3-2.
  • FIG. 7 is a MS diagram of Compound 4-1
  • FIG. 8 is a MS diagram of Compound 4-2.
  • FIG. 9 is a MS diagram of Compound 5-1.
  • FIG. 10 is a MS diagram of Compound 5-2;
  • Figure 11 is a 1 H NMR chart of Compound 7-1;
  • Figure 12 is a 1 H NMR chart of Compound 7-2;
  • Figure 13 is a 1 H NMR chart of Compound M-1;
  • Figure 14 is a 1 H NMR chart of Compound M-2.
  • the compound of the formula 2-1 is replaced with the compound of the formula 2-2, and the compound of the formula 3-2 is obtained by the same method.
  • the compound of the formula 3-1 is replaced with the compound of the formula 3-2, and the compound of the formula 4-2 is obtained by the same method.
  • the compound of the formula 4-1 is replaced with the compound of the formula 4-2, and the compound of the formula 5-2 is obtained by the same method.
  • the compound of the formula 5-1 is replaced with the compound of the formula 5-2, and the compound of the formula 7-2 is obtained by the same method.
  • a compound of the formula 7-1 is replaced with a compound of the formula 7-2, and a compound of the formula M-2 is obtained by the same method.

Abstract

A method for preparing silodosin intermediate is disclosed. Said intermediate has the structure of (M), wherein R is benzyl or benzoyl. Said preparation method has the characteristics of short reaction route, simple operation, low cost, high yield, stable process, etc. The method is suitable for industrial production, and has extra-high industrial application value. Intermediate compounds for preparing the intermediate represented by M are also disclosed.

Description

一种制备西洛多辛中间体的方法Method for preparing silodosin intermediate 技术领域Technical field
本发明属于医药技术领域,具体涉及一种制备西洛多辛中间体的方法以及在该方法中涉及的新的中间体化合物。The invention belongs to the technical field of medicine, and in particular relates to a method for preparing an intermediate of silodosin and a novel intermediate compound involved in the method.
背景技术Background technique
良性前列腺增生(BPH)是中老年男性常见病和多发病,目前临床上用于治疗BPH的药物主要分为两类:α1肾上腺素受体(α-AR)拮抗剂和5α还原酶抑制剂。其中α-AR拮抗剂具有快速、安全、高效的特点。西洛多辛即是一种BPH的α-AR拮抗剂,用于治疗前列腺良性增生所致的排尿困难。Benign prostatic hyperplasia (BPH) is a common and frequently-occurring disease in middle-aged and elderly men. Currently, the drugs used to treat BPH are mainly divided into two categories: α1 adrenergic receptor (α-AR) antagonist and 5α reductase inhibitor. Among them, α-AR antagonists are characterized by fast, safe and efficient. Silodosin is an alpha-AR antagonist of BPH for the treatment of dysuria caused by benign prostatic hyperplasia.
西洛多辛对于尿道平滑肌收缩具有选择性抑制作用,并且降低尿道内压,而对血压没有很大影响,副作用小,因而可用于治疗良性前列腺增生。目前有关西洛多辛的合成方法较多,但缺少工艺简单、收率高、适合工业化大生产的方法。Silodosin has a selective inhibitory effect on urethral smooth muscle contraction, and reduces intraurethral pressure, but has no significant effect on blood pressure, and has few side effects, and thus can be used for treating benign prostatic hyperplasia. At present, there are many synthetic methods for silodosin, but there is a lack of a simple process, high yield, and suitable for industrial large-scale production.
如下式M的光学活性的R-化合物是制备西洛多辛的关键中间体。The optically active R-compound of formula M below is a key intermediate in the preparation of silodosin.
Figure PCTCN2015075757-appb-000001
Figure PCTCN2015075757-appb-000001
JP2002265444报道了式M所示的R-化合物(R1=苯甲基)的制备方法。该方法通过拆分合成过程的中间体羧酸而得到目标产物。该方法合成路线长,拆分收率低,且所用的拆分试剂不易得。JP2002265444 reports the preparation of the R-compound (R 1 = benzyl) represented by the formula M. This method yields the desired product by resolution of the intermediate carboxylic acid of the synthesis. The method has long synthesis route, low resolution, and the resolving agent used is not easy to obtain.
JP2001199956报道了式M所示的R-化合物(R1=苯甲酰基)的制备方法,该方法通过化合物ⅡJP2001199956 reports a process for the preparation of the R-compound (R 1 = benzoyl) represented by the formula M, which passes the compound II
Figure PCTCN2015075757-appb-000002
Figure PCTCN2015075757-appb-000002
与L-苯甘氨醇的不对称还原胺化得到目标产物。该方法采用L-苯甘氨醇,还原胺化得到的非对映异构体混合的下式Ⅲ所示中间体(非对映异构体比例3.8:1), Asymmetric reductive amination with L-phenylglycinol gives the desired product. The method uses L-phenylglycinol, reductive amination to obtain a mixture of diastereomers of the following formula III (diastereomer ratio 3.8:1),
Figure PCTCN2015075757-appb-000003
Figure PCTCN2015075757-appb-000003
然后在Pd/C存在下,催化加氢,脱去苯乙醇部分,最后用L-酒石酸进行光学纯化,得到单一的式M所示的R-化合物(R1=苯甲酰基)。该方法采用了较贵的试剂L-苯甘氨醇及L-酒石酸。Then, in the presence of Pd/C, catalytic hydrogenation, removal of the phenylethyl alcohol fraction, and finally optical purification with L-tartaric acid yields a single R-compound represented by formula M (R 1 = benzoyl). This method uses the more expensive reagents L-phenylglycinol and L-tartaric acid.
JP2006188470报道了式M所示的R-化合物(R1=苯甲基)的制备方法,但该方法中有数步采用柱层析进行纯化,不适于工业化生产。JP2006188470 reports the preparation of the R-compound (R 1 = benzyl) represented by the formula M, but in this method, several steps are carried out by column chromatography, which is not suitable for industrial production.
作为制备西洛多辛的关键中间体,式M的化合物被用以制备西洛多辛在JP2001199956、JP2006188470、WO2011124704中已有报道。As a key intermediate for the preparation of silodosin, a compound of the formula M has been used to prepare sirolimus which has been reported in JP2001199956, JP2006188470, WO2011124704.
发明内容Summary of the invention
基于现有技术在合成西洛多辛时,由于所述关键中间体,即光学活性的化合物M的制备通常使合成工艺复杂化且成本较高,而提出本发明。The present invention has been proposed in the synthesis of silodosin based on the prior art, since the preparation of the key intermediate, optically active compound M, generally complicates the synthesis process and is costly.
本发明的目的在于针对上述不足提供一种西洛多辛中间体的新合成方法。该方法能够提高合成所述化合物的工业化生产可行性,降低危险性和成本。It is an object of the present invention to provide a novel synthesis method of a silodosin intermediate for the above disadvantages. The method can improve the industrial production feasibility of synthesizing the compound, reducing the risk and cost.
本发明一个方面提供式M所示化合物的制备方法,依次包括如下5个步骤:One aspect of the present invention provides a method for preparing a compound of Formula M, which in turn comprises the following five steps:
Figure PCTCN2015075757-appb-000004
Figure PCTCN2015075757-appb-000004
所述方法具体包括下列步骤:The method specifically includes the following steps:
1)将式1的化合物1) Compound of formula 1
Figure PCTCN2015075757-appb-000005
Figure PCTCN2015075757-appb-000005
在存在碱性试剂的碱性条件下,和式2的化合物 a compound of formula 2 in the presence of an alkaline reagent under basic conditions
Figure PCTCN2015075757-appb-000006
Figure PCTCN2015075757-appb-000006
反应,得到式3的化合物Reaction to obtain a compound of formula 3
Figure PCTCN2015075757-appb-000007
Figure PCTCN2015075757-appb-000007
2)将所述式3的化合物和三氯氧磷、N,N-二甲基甲酰胺反应,得到式4的化合物2) reacting the compound of the formula 3 with phosphorus oxychloride and N,N-dimethylformamide to obtain a compound of the formula 4
Figure PCTCN2015075757-appb-000008
Figure PCTCN2015075757-appb-000008
3)将所述式4的化合物和盐酸羟胺反应,得到式5的化合物3) reacting the compound of the formula 4 with hydroxylamine hydrochloride to obtain a compound of the formula 5
Figure PCTCN2015075757-appb-000009
Figure PCTCN2015075757-appb-000009
4)式6的化合物4) Compound of formula 6
Figure PCTCN2015075757-appb-000010
Figure PCTCN2015075757-appb-000010
与锌粉反应制备出有机锌试剂,所述有机锌试剂在钯催化剂和有机配体的催化下,和式5的化合物反应,得到式7的化合物An organozinc reagent is prepared by reacting with zinc powder, and the organozinc reagent is reacted with a compound of formula 5 under the catalysis of a palladium catalyst and an organic ligand to obtain a compound of formula 7
Figure PCTCN2015075757-appb-000011
Figure PCTCN2015075757-appb-000011
5)在酸性条件下,将所述式7的化合物进行脱保护基反应,得到所述式M所示化合物;5) subjecting the compound of the formula 7 to a deprotection reaction under acidic conditions to obtain the compound of the formula M;
其中,R表示苄基或苯甲酰基。Wherein R represents a benzyl group or a benzoyl group.
在一些实施方案中,所述步骤1)-5)均在有机溶剂中进行,所述步骤1)-5)中的有机溶剂各自独立地选自由C1-C4的低级醇、甲苯、二甲苯、冰醋酸、二氯甲烷、1,2-二氯乙烷、二甲亚砜、三氟乙酸、乙酸乙酯、N,N-二甲基甲酰胺及其组合物组成的组。In some embodiments, the steps 1) to 5) are each carried out in an organic solvent, and the organic solvents in the steps 1) to 5) are each independently selected from the group consisting of C 1 -C 4 lower alcohols, toluene, and A group consisting of toluene, glacial acetic acid, dichloromethane, 1,2-dichloroethane, dimethyl sulfoxide, trifluoroacetic acid, ethyl acetate, N,N-dimethylformamide, and combinations thereof.
在一些实施方案中,步骤1)中的所述碱性试剂选自由氢氧化钠、氢氧化钾、碳酸钾、碳酸钠、碘化钾、碳酸氢钠、二异丙基乙二胺、吡啶、胆碱试剂和三乙胺组成的组。In some embodiments, the alkaline agent in step 1) is selected from the group consisting of sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, potassium iodide, sodium hydrogencarbonate, diisopropylethylenediamine, pyridine, choline. A group consisting of a reagent and triethylamine.
在一些实施方案中,所述步骤4)中的所述钯催化剂选自由醋酸钯、四(三苯基膦)钯、氯化钯、[1,1'-双(二苯基膦)二茂铁]二氯化钯、1,1'-双(二苯膦基)二茂铁二氯化钯(II)二 氯甲烷复合物、双(三环己基膦)二氯化钯、双(三苯基膦)二氯化钯(II)、二(二亚苄基丙酮)钯(0)、三(二亚苄基丙酮)二钯氯仿加合物、二(乙酰丙酮)钯(II)、氢氧化钯炭、钯碳、(1,5-环辛二烯)二氯化钯、二(乙腈)二氯化钯(II)、二(苯腈)二氯化钯(II)及其组合组成的组。In some embodiments, the palladium catalyst in step 4) is selected from the group consisting of palladium acetate, tetrakis(triphenylphosphine)palladium, palladium chloride, [1,1'-bis(diphenylphosphine) dioxin Iron] palladium dichloride, 1,1'-bis(diphenylphosphino)ferrocene palladium (II) dichloride Methyl chloride complex, bis(tricyclohexylphosphine)palladium dichloride, bis(triphenylphosphine)palladium(II) dichloride, bis(dibenzylideneacetone)palladium(0), tris(dibenzylidene) Acetone) dipalladium chloroform adduct, di(acetylacetonate)palladium(II), palladium hydroxide carbon, palladium carbon, (1,5-cyclooctadiene) palladium dichloride, di(acetonitrile) dichloride A group consisting of palladium (II), bis(benzonitrile) palladium dichloride (II), and combinations thereof.
在一些实施方案中,所述步骤4)中的所述有机配体选自由三苯基膦、三环己基膦、二苯基环己基膦、4,5-双二苯基膦-9,9-二甲基氧杂蒽、2-二环己基膦-2’,4’,6’-三异丙基联苯、2-双环己基膦-2',6'-二甲氧基联苯、二叔丁基环己基膦、三(邻甲苯基)膦、2-二环己基膦-2',6'-二异丙氧基-1,1'-联苯、1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁、1,1’-双(二苯基膦)二茂铁、2-二叔丁基膦-2’,4’,6’-三异丙基联苯及其组合组成的组。In some embodiments, the organic ligand in step 4) is selected from the group consisting of triphenylphosphine, tricyclohexylphosphine, diphenylcyclohexylphosphine, 4,5-bisdiphenylphosphine-9,9 - dimethylxanthene, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, Di-tert-butylcyclohexylphosphine, tri(o-tolyl)phosphine, 2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl, 1,2,3,4,5 -pentaphenyl-1'-(di-tert-butylphosphine)ferrocene, 1,1'-bis(diphenylphosphino)ferrocene, 2-di-tert-butylphosphine-2',4',6 a group consisting of '-triisopropylbiphenyl and combinations thereof.
在一些实施方案中,所述步骤5)中的所述酸性条件通过加入酸或氯化氢气体获得,其中所述酸选自浓盐酸、三氟乙酸、乙酸或甲酸,其中所述浓盐酸是体积浓度为37%的盐酸。In some embodiments, the acidic condition in step 5) is obtained by adding an acid or a hydrogen chloride gas, wherein the acid is selected from the group consisting of concentrated hydrochloric acid, trifluoroacetic acid, acetic acid or formic acid, wherein the concentrated hydrochloric acid is a volume concentration. It is 37% hydrochloric acid.
优选地,所述步骤4)中的所述钯催化剂选自醋酸钯、二(二亚苄基丙酮)钯(0)、三(二亚苄基丙酮)二钯氯仿加合物或二(乙酰丙酮)钯(II)。Preferably, the palladium catalyst in the step 4) is selected from the group consisting of palladium acetate, bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium chloroform adduct or di(acetyl). Acetone) Palladium (II).
优选地,所述步骤4)中的所述钯催化剂是二(乙酰丙酮)钯(II)。Preferably, the palladium catalyst in the step 4) is bis(acetylacetonate)palladium(II).
优选地,所述步骤4)中的所述有机配体选自三叔丁基膦、2-二环己基膦-2’,4’,6’-三异丙基联苯、2-二环己基膦-2',6'-二异丙氧基-1,1'-联苯、1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁或4,5-双二苯基膦-9,9-二甲基氧杂蒽。Preferably, the organic ligand in the step 4) is selected from the group consisting of tri-tert-butylphosphine, 2-dicyclohexylphosphine-2', 4',6'-triisopropylbiphenyl, 2-bicyclic ring Hexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl, 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphine)ferrocene Or 4,5-bisdiphenylphosphino-9,9-dimethyloxazepine.
优选地,所述步骤4)中的所述有机配体是1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁。Preferably, the organic ligand in the step 4) is 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphine)ferrocene.
在一些实施方案中,所述步骤1)、所述步骤2)和所述步骤3)的反应温度为50~200℃,反应时间为1~10h,优选反应温度为60~150℃,反应时间为3~8h。In some embodiments, the reaction temperature of the step 1), the step 2) and the step 3) is 50 to 200 ° C, the reaction time is 1 to 10 h, preferably the reaction temperature is 60 to 150 ° C, and the reaction time is It is 3 to 8 hours.
在一些实施方案中,所述步骤4)和所述步骤5)的反应温度为-20~50℃,反应时间为1~10h,优选反应温度为-10~30℃,反应时间为1~5h。In some embodiments, the reaction temperature of the step 4) and the step 5) is -20 to 50 ° C, the reaction time is 1 to 10 h, preferably the reaction temperature is -10 to 30 ° C, and the reaction time is 1 to 5 h. .
本发明的一个方面提供了在上述制备方法中涉及的新的中间体化合物:One aspect of the present invention provides novel intermediate compounds involved in the above preparation methods:
Figure PCTCN2015075757-appb-000012
Figure PCTCN2015075757-appb-000012
Figure PCTCN2015075757-appb-000013
Figure PCTCN2015075757-appb-000013
本发明的一个方面提供一种制备式6所示化合物的方法,包括如下步骤:One aspect of the present invention provides a method of preparing a compound of Formula 6, comprising the steps of:
Figure PCTCN2015075757-appb-000014
Figure PCTCN2015075757-appb-000014
所述方法具体包括下列步骤:The method specifically includes the following steps:
1)将由式SLD-9C所示的化合物,在包含有机溶剂、回流的条件下,与氯化亚砜反应3-10个小时,得到式SLD-8C所示的化合物,1) A compound represented by the formula SLD-9C is reacted with thionyl chloride for 3 to 10 hours under an organic solvent-containing reflux condition to obtain a compound represented by the formula SLD-8C.
Figure PCTCN2015075757-appb-000015
Figure PCTCN2015075757-appb-000015
2)式SLD-8C所示的化合物在有机溶剂中,碱性条件下,与二碳酸二叔丁酯反应3-7个小时,得到SLD-7C所示的化合物,2) The compound represented by the formula SLD-8C is reacted with di-tert-butyl dicarbonate in an organic solvent under basic conditions for 3-7 hours to obtain a compound represented by SLD-7C.
Figure PCTCN2015075757-appb-000016
Figure PCTCN2015075757-appb-000016
3)式SLD-7C所示的化合物在有机溶剂中,碱性条件下,和硼氢化钠反应,得到式SLD-6C所示的化合物,3) The compound represented by the formula SLD-7C is reacted with sodium borohydride in an organic solvent under basic conditions to obtain a compound represented by the formula SLD-6C.
Figure PCTCN2015075757-appb-000017
Figure PCTCN2015075757-appb-000017
4)式SLD-6C所示的化合物在三苯基膦、有机溶剂中,与碘反应,得到式6所示的化合物,4) a compound represented by the formula SLD-6C is reacted with iodine in triphenylphosphine or an organic solvent to obtain a compound represented by the formula 6,
Figure PCTCN2015075757-appb-000018
Figure PCTCN2015075757-appb-000018
本领域技术人员应当了解,上述反应条件,包括前述的合成式M所示化合物的反应 条件,并不是实现本发明技术方案的唯一方式。本领域技术人员可以在不脱离本发明宗旨的基础上,按照实际需要对所述反应条件进行更改而实现本发明的技术方案。Those skilled in the art will appreciate that the above reaction conditions include the aforementioned reaction of the compound of the formula M. Conditions are not the only way to implement the technical solution of the present invention. Those skilled in the art can implement the technical solution of the present invention by modifying the reaction conditions according to actual needs without departing from the gist of the present invention.
本发明的优点在于:通过本发明方法合成的式M所示化合物,可作为中间体化合物用以合成西洛多辛。该方法具有以下优势:An advantage of the present invention is that the compound of formula M synthesized by the process of the invention can be used as an intermediate compound for the synthesis of sirolimus. This method has the following advantages:
1.缩短了反应路线,降低了生产成本;1. Shorten the reaction route and reduce production costs;
2.纯度高,收率好;2. High purity and good yield;
3.反应条件温和,并且操作简单、适合于工业化生产。3. The reaction conditions are mild, and the operation is simple and suitable for industrial production.
附图说明DRAWINGS
图1是化合物SLD-8C的1H NMR图;Figure 1 is a 1 H NMR chart of the compound SLD-8C;
图2是化合物SLD-7C的1H NMR图;Figure 2 is a 1 H NMR chart of the compound SLD-7C;
图3是化合物SLD-6C的1H NMR图;Figure 3 is a 1 H NMR chart of the compound SLD-6C;
图4是化合物6的1H NMR图;Figure 4 is a 1 H NMR chart of Compound 6;
图5是化合物3-1的MS图;Figure 5 is a MS diagram of Compound 3-1;
图6是化合物3-2的MS图;Figure 6 is a MS diagram of Compound 3-2;
图7是化合物4-1的MS图;Figure 7 is a MS diagram of Compound 4-1;
图8是化合物4-2的MS图;Figure 8 is a MS diagram of Compound 4-2;
图9是化合物5-1的MS图;Figure 9 is a MS diagram of Compound 5-1;
图10是化合物5-2的MS图;Figure 10 is a MS diagram of Compound 5-2;
图11是化合物7-1的1H NMR图;Figure 11 is a 1 H NMR chart of Compound 7-1;
图12是化合物7-2的1H NMR图;Figure 12 is a 1 H NMR chart of Compound 7-2;
图13是化合物M-1的1H NMR图;以及Figure 13 is a 1 H NMR chart of Compound M-1;
图14是化合物M-2的1H NMR图。Figure 14 is a 1 H NMR chart of Compound M-2.
具体实施方式detailed description
以下将结合具体实施方案来说明本发明。需要说明的是,下面的实施例为本发明的示例,仅用来说明本发明,而不用来限制本发明。The invention will now be described in connection with specific embodiments. It is to be understood that the following examples are illustrative of the invention and are not intended to limit the invention.
实施例1Example 1
1)化合物SLD-8C的制备1) Preparation of compound SLD-8C
Figure PCTCN2015075757-appb-000019
Figure PCTCN2015075757-appb-000019
称取107g SLD-9C(市售)加入到2L三口瓶中,加入600mL甲醇,机械搅拌并冰水浴下滴加131mL氯化亚砜,并搭建尾气吸收装置,滴完后回流反应5~8h。 Weigh 107g of SLD-9C (commercially available) into 2L three-necked flask, add 600mL of methanol, mechanically stir and add 131mL of thionyl chloride under ice water bath, and build a tail gas absorption device. After the completion of the drip, reflux reaction for 5-8h.
TLC监测反应完全后,直接浓缩蒸除甲醇,用120mL*3甲苯洗涤,浓缩蒸除残留甲苯,油泵抽24h,得到167g白色固体SLD-8C,收率:99.6%。After the reaction was completely monitored by TLC, methanol was directly concentrated and evaporated, washed with 120 mL of 3 toluene, and concentrated toluene was evaporated. The oil was pumped for 24 hours to obtain 167 g of white solid SLD-8C. Yield: 99.6%.
1H-NMR(d6-DMSO)δ:8.71(s,1H);8.52(s,2H);3.71~4.05(m,1H);3.36~3.46(s,3H);1.19~1.62(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 8.71 (s, 1H); 8.52 (s, 2H); 3.71 to 4.05 (m, 1H); 3.36 to 3.46 (s, 3H); 1.19 to 1.62 (d, 3H).
化合物SLD-8C的1H NMR图参见图1。See Figure 1 for the 1 H NMR chart of the compound SLD-8C.
3)化合物SLD-7C的制备3) Preparation of compound SLD-7C
Figure PCTCN2015075757-appb-000020
Figure PCTCN2015075757-appb-000020
称取167g SLD-8C,242g三乙胺,1L二氯甲烷加入到2L三口瓶中,滴加313g二碳酸二叔丁酯,再次加入200mL二氯甲烷,室温反应5h。167 g of SLD-8C, 242 g of triethylamine were weighed, 1 L of dichloromethane was added to a 2 L three-necked flask, 313 g of di-tert-butyl dicarbonate was added dropwise, and 200 mL of dichloromethane was again added thereto, and reacted at room temperature for 5 hours.
TLC监测反应完全后,水淬灭,分出二氯甲烷,并用二氯甲烷萃取(500mL*2),合并有机相,水洗2次,无水硫酸钠干燥,蒸除溶剂,柱层析后得到红色液体224g SLD-7C,收率:92.2%。After the reaction was completed by TLC, water was quenched, dichloromethane was separated, and extracted with dichloromethane (500 mL*2). The organic phase was combined, washed twice with water, dried over anhydrous sodium sulfate and evaporated. Red liquid 224 g SLD-7C, yield: 92.2%.
1H-NMR(d6-DMSO)δ:7.26~7.28(d,1H);3.86~4.18(m,1H);3.61(s,3H);1.33~1.37(s,9H);0.97~1.02(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 7.26 to 7.28 (d, 1H); 3.86 to 4.18 (m, 1H); 3.61 (s, 3H); 1.33 to 1.37 (s, 9H); 0.97 to 1.02 ( d, 3H).
化合物SLD-7C的1H NMR图参见图2。See Figure 2 for the 1 H NMR chart of the compound SLD-7C.
4)化合物SLD-6C的制备4) Preparation of compound SLD-6C
Figure PCTCN2015075757-appb-000021
Figure PCTCN2015075757-appb-000021
称取134g氯化钙研碎后加入到2L三口瓶中,加入400mL甲醇和500mL四氢呋喃,加入甲醇过程中用冰水浴冷却,稍冷后分批加入92g硼氢化钠,搅拌0.5h后滴加224gSLD-7C(溶于200mL四氢呋喃),室温搅拌1h后慢慢升温至70℃,反应15~20h。134g of calcium chloride was weighed and added to a 2L three-necked flask. 400mL of methanol and 500mL of tetrahydrofuran were added. After adding methanol, it was cooled in an ice water bath. After a little cold, 92g of sodium borohydride was added in batches. After stirring for 0.5h, 224g of SLD was added dropwise. -7C (dissolved in 200 mL of tetrahydrofuran), stirred at room temperature for 1 h, then slowly warmed to 70 ° C, and reacted for 15-20 h.
TLC监测反应完全后,倒入大量冰水中淬灭,滤出固体残渣,残渣用二氯甲烷洗三次(500mL*3),分出有机层,水层用二氯甲烷1L*2萃取,合并有机层,水洗两次,无水硫酸钠干燥,蒸除溶剂,得到185g白色固体SLD-6C,收率:95.8%。After the reaction was completed by TLC, it was poured into a large amount of ice water and quenched, and the solid residue was filtered. The residue was washed three times with dichloromethane (500 mL*3), the organic layer was separated, and the aqueous layer was extracted with dichloromethane 1L*2. The layer was washed twice with water and dried over anhydrous sodium sulfate, and evaporated to give 185 g of white solid.
1H-NMR(d6-DMSO)δ:6.48~6.51(d,1H);4.56~4.59(m,1H);3.47~3.61(m,1H);3.26~3.45(m,1H);3.11~3.18(m,1H);1.47(s,9H);0.85~0.96(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 6.48 to 6.51 (d, 1H); 4.56 to 4.59 (m, 1H); 3.47 to 3.61 (m, 1H); 3.26 to 3.45 (m, 1H); 3.18 (m, 1H); 1.47 (s, 9H); 0.85 to 0.96 (d, 3H).
化合物SLD-6C的1H NMR图参见图3。See Figure 3 for the 1 H NMR chart of the compound SLD-6C.
5)化合物6的制备5) Preparation of Compound 6
Figure PCTCN2015075757-appb-000022
Figure PCTCN2015075757-appb-000022
称取187.6g三苯基、48.7g咪唑加入到2L三口瓶中,加入1L二氯甲烷,分批加入200g碘,用冰水浴保持温度在30℃以下,加完搅拌10min后,将125.3g SLD-6C溶于200mL二氯甲烷,滴加入反应液中,滴完后室温反应10~20h。Weigh 187.6 g of triphenyl and 48.7 g of imidazole into a 2 L three-necked flask, add 1 L of dichloromethane, add 200 g of iodine in portions, keep the temperature below 30 ° C with an ice water bath, and add 125.3 g of SLD after stirring for 10 min. -6C was dissolved in 200 mL of dichloromethane, added dropwise to the reaction solution, and reacted at room temperature for 10-20 h after the completion of the dropwise addition.
TLC监测反应完全后,倒入水中淬灭,分出有机层,水层用500mL*2二氯甲烷萃取,合并有机层,水洗两次,无水硫酸钠干燥,减压浓缩干溶剂,柱层析得到粗产品,石油醚+二氯甲烷重结晶得到60g白色固体6,收率:29.4%。After the reaction was completed by TLC, it was poured into water and quenched, and the organic layer was separated. The aqueous layer was extracted with 500 mL*2 dichloromethane. The organic layer was combined, washed twice, dried over anhydrous sodium sulfate and concentrated The crude product was obtained, crystallized from petroleum ether & methylene chloride to afford 60 g of white solids (yield: 29.4%).
1H-NMR(d6-DMSO)δ:6.96(m,1H);3.46~3.51(m,1H);3.19~3.31(m,2H);1.39~1.48(s,9H);0.99~1.12(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 6.96 (m, 1H); 3.46 to 3.51 (m, 1H); 3.19 to 3.31 (m, 2H); 1.39 to 1.48 (s, 9H); 0.99 to 1.12 ( d, 3H).
化合物6的1H NMR图参见图4。See Figure 4 for the 1 H NMR chart of Compound 6.
6)化合物3-1的制备6) Preparation of Compound 3-1
Figure PCTCN2015075757-appb-000023
Figure PCTCN2015075757-appb-000023
称取85g化合物1、80g化合物2-1、4g碘化钾、98g K2CO3加入到装有400mL DMF(N,N-二甲基甲酰胺)的三口烧瓶中,升温到120℃,反应5h。反应结束后,加入800mL乙酸乙酯和200mL水,以300mL水洗乙酸乙酯,反复洗4次,干燥,减压浓缩干溶剂,柱层析,得到100g黄色液体(化合物3-1),收率67%。85 g of the compound 1, 80 g of the compound 2-1, 4 g of potassium iodide, and 98 g of K 2 CO 3 were weighed and added to a three-necked flask containing 400 mL of DMF (N,N-dimethylformamide), and the mixture was heated to 120 ° C for 5 hours. After completion of the reaction, 800 mL of ethyl acetate and 200 mL of water were added, and ethyl acetate was washed with 300 mL of water, and washed four times, and dried, and the solvent was concentrated under reduced pressure, and purified by column chromatography to give 100 g of a yellow liquid (Compound 3-1). 67%.
在此步骤中,将式2-1的化合物替换成式2-2的化合物,通过同样的方法,得到式3-2的化合物In this step, the compound of the formula 2-1 is replaced with the compound of the formula 2-2, and the compound of the formula 3-2 is obtained by the same method.
Figure PCTCN2015075757-appb-000024
Figure PCTCN2015075757-appb-000024
化合物3-1的MS图参见图5;以及See Figure 5 for the MS diagram of Compound 3-1;
化合物3-2的MS图参见图6。See Figure 6 for the MS map of Compound 3-2.
7)化合物4-1的制备 7) Preparation of Compound 4-1
Figure PCTCN2015075757-appb-000025
Figure PCTCN2015075757-appb-000025
称取30g三氯氧磷、量取250mL DMF,加入到1L三口瓶中,氮气置换3次。升温到80℃,反应1h,然后加50g化合物3-1,继续反应3h。TCL检测反应结束后,将反应液加到氢氧化钠的水溶液中,乙酸乙酯萃取,干燥,减压浓缩干溶剂,柱层析,得到40g微黄色固体(化合物4-1)。MS m/z:373(M+),收率:74.1%。Weigh 30 g of phosphorus oxychloride, measure 250 mL of DMF, add to a 1 L three-necked flask, and replace with nitrogen three times. The temperature was raised to 80 ° C, and the reaction was carried out for 1 h, then 50 g of compound 3-1 was added, and the reaction was continued for 3 h. After the TCL detection reaction was completed, the reaction solution was added to an aqueous solution of sodium hydroxide, extracted with ethyl acetate, and dried, and the solvent was evaporated to vacuo. MS m/z: 373 (M + ), yield: 74.1%.
在此步骤中,将式3-1的化合物替换成式3-2的化合物,通过同样的方法,得到式4-2的化合物In this step, the compound of the formula 3-1 is replaced with the compound of the formula 3-2, and the compound of the formula 4-2 is obtained by the same method.
Figure PCTCN2015075757-appb-000026
Figure PCTCN2015075757-appb-000026
化合物4-1的MS图参见图7;以及See Figure 7 for the MS diagram of Compound 4-1;
化合物4-2的MS图参见图8。See Figure 8 for the MS map of Compound 4-2.
8)化合物5-1的制备8) Preparation of Compound 5-1
Figure PCTCN2015075757-appb-000027
Figure PCTCN2015075757-appb-000027
称取40g化合物4-1加入到1L单口瓶中,加入500mL DMSO(二甲基亚砜)、15g盐酸羟胺,升温到100℃,反应8h。TLC监测反应完全后,加大量水,析出大量固体,过滤,柱层析,得到30g白色固体。MS m/z:370(M+),收率:75%。40 g of Compound 4-1 was weighed into a 1 L single-mouth bottle, 500 mL of DMSO (dimethyl sulfoxide) and 15 g of hydroxylamine hydrochloride were added, and the temperature was raised to 100 ° C for 8 hours. After the reaction was completed by TLC, a large amount of water was added, and a large amount of solids were precipitated, which was filtered and subjected to column chromatography to obtain 30 g of a white solid. MS m/z: 370 (M + ), yield: 75%.
在此步骤中,将式4-1的化合物替换成式4-2的化合物,通过同样的方法,得到式5-2的化合物In this step, the compound of the formula 4-1 is replaced with the compound of the formula 4-2, and the compound of the formula 5-2 is obtained by the same method.
Figure PCTCN2015075757-appb-000028
Figure PCTCN2015075757-appb-000028
化合物5-1的MS图参见图9;以及See Figure 9 for the MS map of Compound 5-1;
化合物5-2的MS图参见图10。See Figure 10 for the MS map of Compound 5-2.
9)化合物7-1的制备 9) Preparation of Compound 7-1
Figure PCTCN2015075757-appb-000029
Figure PCTCN2015075757-appb-000029
称取21g Zn粉和25mL干燥过的四氢呋喃,氮气置换气3次,搅拌,冷却到0℃,滴加23g化合物6和25mL干燥过的四氢呋喃的混合溶液,滴毕,室温搅拌反应1.5h。加入30g化合物5-1,1.2g二(乙酰丙酮)钯(II),6.8g 1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁,氮气置换气3次,室温反应1.5h。TCL检测反应结束后,加大量水,析出固体,过滤,乙酸乙酯(25mL)和石油醚(80mL)重结晶。得到28g白色固体(化合物7-1),收率:75%。21 g of Zn powder and 25 mL of dried tetrahydrofuran were weighed, the gas was replaced with nitrogen three times, stirred, and cooled to 0 ° C, and a mixed solution of 23 g of compound 6 and 25 mL of dried tetrahydrofuran was added dropwise, and the mixture was stirred at room temperature for 1.5 h. 30 g of compound 5-1, 1.2 g of bis(acetylacetonate)palladium(II), 6.8 g of 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphino)ferrocene, nitrogen The gas was replaced three times and reacted at room temperature for 1.5 h. After the TCL detection reaction was completed, a large amount of water was added, and the solid was separated, filtered, ethyl acetate (25mL) and petroleum ether (80mL). 28 g of a white solid (Compound 7-1) were obtained in a yield: 75%.
1H-NMR(d6-DMSO)δ:7.981(t,2H);7.645(t,1H);7.499(t,2H);7.038(s,1H);6.944(s,1H);6.696(d,1H);4.369(t,2H);3.670(t,2H);3.557(s,2H);2.913(s,2H);2.506~2.467(m,2H);2.093~1.984(m,2H);1.317(s,9H);1.0(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 7.981 (t, 2H); 7.645 (t, 1H); 7.499 (t, 2H); 7. s (s, 1H); 6.944 (s, 1H); , 1H); 4.369 (t, 2H); 3.670 (t, 2H); 3.557 (s, 2H); 2.913 (s, 2H); 2.506 to 2.467 (m, 2H); 2.093 to 1.984 (m, 2H); 1.317 (s, 9H); 1.0 (d, 3H).
在此步骤中,将式5-1的化合物替换成式5-2的化合物,通过同样的方法,得到式7-2的化合物In this step, the compound of the formula 5-1 is replaced with the compound of the formula 5-2, and the compound of the formula 7-2 is obtained by the same method.
Figure PCTCN2015075757-appb-000030
Figure PCTCN2015075757-appb-000030
1H-NMR(d6-DMSO)δ:7.265~7.336(m,5H);7.030(s,1H);6.934(s,1H);6.675~6.702(d,1H);3.484~3.575(m,7H);2.866~2.924(t,2H);2.494~2.506(M,2H);1.832~1.879(t,2H);1.324(s,9H);0.981~1.002(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 7.265 to 7.336 (m, 5H); 7.030 (s, 1H); 6.934 (s, 1H); 6.765 to 6.702 (d, 1H); 3.484 to 3.575 (m, 7H); 2.866 to 2.924 (t, 2H); 2.494 to 2.506 (M, 2H); 1.832 to 1.879 (t, 2H); 1.324 (s, 9H); 0.981 to 1.002 (d, 3H).
化合物7-1的1H NMR图参见图11;以及The 1 H NMR chart of Compound 7-1 is shown in Figure 11;
化合物7-2的1H NMR图参见图12。See Figure 12 for the 1 H NMR chart of Compound 7-2.
10)化合物M-1的制备10) Preparation of Compound M-1
Figure PCTCN2015075757-appb-000031
Figure PCTCN2015075757-appb-000031
称取28g化合物7-1加到25mL三氟乙酸中,回流3h,加氢氧化钠的水溶液调pH=10,乙醇萃取,干燥,旋干。得到21g白色固体(化合物M-1),收率:96%。28 g of compound 7-1 was weighed and added to 25 mL of trifluoroacetic acid, refluxed for 3 h, adjusted to pH = 10 with aqueous sodium hydroxide solution, extracted with ethanol, dried and dried. 21 g of a white solid (Compound M-1) was obtained in a yield: 96%.
1H-NMR(d6-DMSO)δ:8.003(d,2H);7.705(t,1H);7.499(t,2H);7.050(s,1H);6.955(s,1H);4.369(t,2H);3.670(t,2H);3.557(s,2H);2.928~2.897(m,3H);2.382(d,2H); 2.180~1.985(m,2H);0.938(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 8.003 (d, 2H); 7.705 (t, 1H); 7.499 (t, 2H); 7.050 (s, 1H); 6.955 (s, 1H); 4.369 (t) , 2H); 3.670 (t, 2H); 3.557 (s, 2H); 2.928 to 2.879 (m, 3H); 2.382 (d, 2H); 2.180 to 1.985 (m, 2H); 0.938 (d, 3H).
在此步骤中,将式7-1的化合物替换成式7-2的化合物,通过同样的方法,得到式M-2的化合物In this step, a compound of the formula 7-1 is replaced with a compound of the formula 7-2, and a compound of the formula M-2 is obtained by the same method.
Figure PCTCN2015075757-appb-000032
Figure PCTCN2015075757-appb-000032
1H-NMR(d6-DMSO)δ:7.2775~7.333(m,5H);7.032(s,1H);6.938(s,1H);3.480~3.581(m,6H);2.866~2.926(t,3H);2.341~2.363(d,2H);1.862~1.908(t,2H);0.910~0.931(d,3H)。 1 H-NMR (d 6 -DMSO) δ: 7.2775 - 7.333 (m, 5H); 7.032 (s, 1H); 6.938 (s, 1H); 3.480 to 3.581 (m, 6H); 2.866 to 2.926 (t, 3H); 2.341 to 2.363 (d, 2H); 1.862 to 1.908 (t, 2H); 0.910 to 0.931 (d, 3H).
化合物M-1的1H NMR图参见图13;以及The 1 H NMR chart of Compound M-1 is shown in Figure 13;
化合物M-2的1H NMR图参见图14。 See Figure 14 for the 1 H NMR chart of Compound M-2.

Claims (14)

  1. 一种制备式M所示化合物的方法,A method of preparing a compound of formula M,
    Figure PCTCN2015075757-appb-100001
    Figure PCTCN2015075757-appb-100001
    所述方法包括以下步骤:The method includes the following steps:
    1)将式1的化合物1) Compound of formula 1
    Figure PCTCN2015075757-appb-100002
    Figure PCTCN2015075757-appb-100002
    在存在碱性试剂的碱性条件下,和式2的化合物a compound of formula 2 in the presence of an alkaline reagent under basic conditions
    Figure PCTCN2015075757-appb-100003
    Figure PCTCN2015075757-appb-100003
    反应,得到式3的化合物Reaction to obtain a compound of formula 3
    Figure PCTCN2015075757-appb-100004
    Figure PCTCN2015075757-appb-100004
    2)将所述式3的化合物和三氯氧磷、N,N-二甲基甲酰胺反应,得到式4的化合物2) reacting the compound of the formula 3 with phosphorus oxychloride and N,N-dimethylformamide to obtain a compound of the formula 4
    Figure PCTCN2015075757-appb-100005
    Figure PCTCN2015075757-appb-100005
    3)将所述式4的化合物和盐酸羟胺反应,得到式5的化合物3) reacting the compound of the formula 4 with hydroxylamine hydrochloride to obtain a compound of the formula 5
    Figure PCTCN2015075757-appb-100006
    Figure PCTCN2015075757-appb-100006
    4)式6的化合物4) Compound of formula 6
    Figure PCTCN2015075757-appb-100007
    Figure PCTCN2015075757-appb-100007
    与锌粉反应制备出有机锌试剂,所述有机锌试剂在钯催化剂和有机配体的催化下,和式5的化合物反应,得到式7的化合物An organozinc reagent is prepared by reacting with zinc powder, and the organozinc reagent is reacted with a compound of formula 5 under the catalysis of a palladium catalyst and an organic ligand to obtain a compound of formula 7
    Figure PCTCN2015075757-appb-100008
    Figure PCTCN2015075757-appb-100008
    5)在酸性条件下,将所述式7的化合物进行脱保护基反应,得到所述式M所示化合物; 5) subjecting the compound of the formula 7 to a deprotection reaction under acidic conditions to obtain the compound of the formula M;
    其中,R表示苄基或苯甲酰基。Wherein R represents a benzyl group or a benzoyl group.
  2. 如权利要求1所述的方法,其中所述步骤1)-5)均在有机溶剂中进行,所述步骤1)-5)中的有机溶剂各自独立地选自由C1-C4的低级醇、甲苯、二甲苯、冰醋酸、二氯甲烷、1,2-二氯乙烷、二甲亚砜、三氟乙酸、乙酸乙酯、N,N-二甲基甲酰胺及其组合组成的组。The method according to claim 1, wherein said steps 1) to 5) are each carried out in an organic solvent, and the organic solvents in said steps 1) to 5) are each independently selected from lower alcohols of C 1 - C 4 a group consisting of toluene, xylene, glacial acetic acid, dichloromethane, 1,2-dichloroethane, dimethyl sulfoxide, trifluoroacetic acid, ethyl acetate, N,N-dimethylformamide, and combinations thereof .
  3. 如权利要求1所述的方法,其中步骤1)中的所述碱性试剂选自由氢氧化钠、氢氧化钾、碳酸钾、碳酸钠、碘化钾、碳酸氢钠、二异丙基乙二胺、吡啶、胆碱试剂和三乙胺组成的组。The method of claim 1 wherein said alkaline agent in step 1) is selected from the group consisting of sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, potassium iodide, sodium hydrogencarbonate, diisopropylethylenediamine, a group consisting of pyridine, choline reagent and triethylamine.
  4. 如权利要求1所述的方法,其中所述步骤4)中的所述钯催化剂选自由醋酸钯、四(三苯基膦)钯、氯化钯、[1,1'-双(二苯基膦)二茂铁]二氯化钯、1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物、双(三环己基膦)二氯化钯、双(三苯基膦)二氯化钯(II)、二(二亚苄基丙酮)钯(0)、三(二亚苄基丙酮)二钯氯仿加合物、二(乙酰丙酮)钯(II)、氢氧化钯炭、钯碳、(1,5-环辛二烯)二氯化钯、二(乙腈)二氯化钯(II)、二(苯腈)二氯化钯(II)及其组合组成的组。The method of claim 1 wherein said palladium catalyst in said step 4) is selected from the group consisting of palladium acetate, tetrakis(triphenylphosphine)palladium, palladium chloride, [1,1'-bis(diphenyl) Phosphine) ferrocene] palladium dichloride, 1,1'-bis(diphenylphosphino)ferrocene palladium (II) dichloromethane complex, bis(tricyclohexylphosphine) palladium dichloride , bis(triphenylphosphine)palladium(II) dichloride, bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium chloroform adduct, di(acetylacetonate)palladium (II), palladium hydroxide carbon, palladium carbon, (1,5-cyclooctadiene) palladium dichloride, di(acetonitrile) palladium (II) dichloride, bis(benzonitrile) palladium dichloride (II) ) and its combination of groups.
  5. 如权利要求1所述的方法,其中所述步骤4)中的所述有机配体选自由三苯基膦、三环己基膦、二苯基环己基膦、4,5-双二苯基膦-9,9-二甲基氧杂蒽、2-二环己基膦-2’,4’,6’-三异丙基联苯、2-双环己基膦-2',6'-二甲氧基联苯、二叔丁基环己基膦、三(邻甲苯基)膦、2-二环己基膦-2',6'-二异丙氧基-1,1'-联苯、1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁、1,1’-双(二苯基膦)二茂铁、2-二叔丁基膦-2’,4’,6’-三异丙基联苯及其组合组成的组。The method of claim 1 wherein said organic ligand in said step 4) is selected from the group consisting of triphenylphosphine, tricyclohexylphosphine, diphenylcyclohexylphosphine, 4,5-bisdiphenylphosphine. -9,9-Dimethyloxanthene, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphine-2',6'-dimethoxy Biphenyl, di-tert-butylcyclohexylphosphine, tri(o-tolyl)phosphine, 2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl, 1,2,3 , 4,5-pentaphenyl-1'-(di-tert-butylphosphine)ferrocene, 1,1'-bis(diphenylphosphino)ferrocene, 2-di-tert-butylphosphine-2', A group consisting of 4',6'-triisopropylbiphenyl and combinations thereof.
  6. 如权利要求1所述的方法,其中所述步骤5)中的所述酸性条件通过加入酸或氯化氢气体获得,其中所述酸选自由37%的盐酸、三氟乙酸、乙酸和甲酸组成的组。The method according to claim 1, wherein said acidic condition in said step 5) is obtained by adding an acid or a hydrogen chloride gas, wherein said acid is selected from the group consisting of 37% hydrochloric acid, trifluoroacetic acid, acetic acid and formic acid. .
  7. 如权利要求4所述的方法,其中所述步骤4)中的所述钯催化剂选自由醋酸钯、二(二亚苄基丙酮)钯(0)、三(二亚苄基丙酮)二钯氯仿加合物和二(乙酰丙酮)钯(II)组成的组。The method according to claim 4, wherein said palladium catalyst in said step 4) is selected from the group consisting of palladium acetate, bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium chloroform. A group consisting of an adduct and bis(acetylacetonate)palladium(II).
  8. 如权利要求7所述的方法,其中所述步骤4)中的所述钯催化剂是二(乙酰丙酮)钯(II)。The method of claim 7 wherein said palladium catalyst in said step 4) is bis(acetylacetonate)palladium(II).
  9. 如权利要求5所述的方法,其中所述步骤4)中的所述有机配体选自由三叔丁基膦、2-二环己基膦-2’,4’,6’-三异丙基联苯、2-二环己基膦-2',6'-二异丙氧基-1,1'-联苯、1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁和4,5-双二苯基膦-9,9-二甲基氧杂蒽组成的组。The method according to claim 5, wherein said organic ligand in said step 4) is selected from the group consisting of tri-tert-butylphosphine, 2-dicyclohexylphosphine-2', 4', 6'-triisopropyl Biphenyl, 2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl, 1,2,3,4,5-pentaphenyl-1'-(di-tert A group consisting of butylphosphine) ferrocene and 4,5-bisdiphenylphosphino-9,9-dimethyloxaxime.
  10. 如权利要求9所述的方法,其中所述步骤4)中的所述有机配体是1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁。 The method according to claim 9, wherein said organic ligand in said step 4) is 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphine)ferrocene. .
  11. 一种如下式所示的化合物:A compound of the formula:
    Figure PCTCN2015075757-appb-100009
    Figure PCTCN2015075757-appb-100009
  12. 一种如下式所示的化合物:A compound of the formula:
    Figure PCTCN2015075757-appb-100010
    Figure PCTCN2015075757-appb-100010
  13. 一种如下式所示的化合物:A compound of the formula:
    Figure PCTCN2015075757-appb-100011
    Figure PCTCN2015075757-appb-100011
  14. 一种如下式所示的化合物:A compound of the formula:
    Figure PCTCN2015075757-appb-100012
    Figure PCTCN2015075757-appb-100012
PCT/CN2015/075757 2014-04-10 2015-04-02 Method for preparing silodosin intermediate WO2015154637A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410144175.XA CN104974073B (en) 2014-04-10 2014-04-10 A kind of method for preparing Silodosin intermediate
CN201410144175.X 2014-04-10

Publications (1)

Publication Number Publication Date
WO2015154637A1 true WO2015154637A1 (en) 2015-10-15

Family

ID=54271090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/075757 WO2015154637A1 (en) 2014-04-10 2015-04-02 Method for preparing silodosin intermediate

Country Status (2)

Country Link
CN (1) CN104974073B (en)
WO (1) WO2015154637A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421719B2 (en) 2015-09-30 2019-09-24 Urquima S.A. Maleic acid salt of a silodosin intermediate
CN113461910A (en) * 2021-07-02 2021-10-01 江苏大学 Polyethylidene norbornene divinyl biphenyl copolymer and preparation method thereof
CN115197043A (en) * 2022-07-05 2022-10-18 中国石油大学(华东) Perylene dimer connected by covalent bond and preparation method thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109574903A (en) * 2017-09-28 2019-04-05 安徽省庆云医药股份有限公司 A method of preparing Silodosin intermediate
CN109574902B (en) * 2017-09-28 2022-07-01 安徽省庆云医药股份有限公司 Preparation method of silodosin intermediate
CN111471003B (en) * 2019-01-24 2022-09-23 上海皓元医药股份有限公司 Preparation method of sitagliptin intermediate
CN114805170B (en) * 2021-01-29 2024-03-29 四川青木制药有限公司 Preparation method of novel silodosin chiral intermediate
CN114751852B (en) * 2022-05-23 2023-09-15 山西库邦生物医药科技有限公司 Preparation method of silodosin key intermediate
CN115838349B (en) * 2023-02-20 2023-07-14 南京桦冠生物技术有限公司 Preparation method of 3- (7-cyano-5- (2-oxo propyl) indoline-1-yl) propyl benzoate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199956A (en) * 2000-01-14 2001-07-24 Kissei Pharmaceut Co Ltd Method for producing optically active indoline derivative and intermediate for producing the derivative
CN101993407A (en) * 2009-08-27 2011-03-30 浙江华海药业股份有限公司 Indoline compound for preparing silodosin and preparation method thereof
CN103420893A (en) * 2013-08-02 2013-12-04 江苏和成新材料有限公司 Method for preparing silodosin intermediate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009005024A1 (en) * 2007-07-03 2009-01-08 Hamari Chemicals, Ltd. Method for producing optically active amine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199956A (en) * 2000-01-14 2001-07-24 Kissei Pharmaceut Co Ltd Method for producing optically active indoline derivative and intermediate for producing the derivative
CN101993407A (en) * 2009-08-27 2011-03-30 浙江华海药业股份有限公司 Indoline compound for preparing silodosin and preparation method thereof
CN103420893A (en) * 2013-08-02 2013-12-04 江苏和成新材料有限公司 Method for preparing silodosin intermediate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421719B2 (en) 2015-09-30 2019-09-24 Urquima S.A. Maleic acid salt of a silodosin intermediate
CN113461910A (en) * 2021-07-02 2021-10-01 江苏大学 Polyethylidene norbornene divinyl biphenyl copolymer and preparation method thereof
CN115197043A (en) * 2022-07-05 2022-10-18 中国石油大学(华东) Perylene dimer connected by covalent bond and preparation method thereof

Also Published As

Publication number Publication date
CN104974073A (en) 2015-10-14
CN104974073B (en) 2017-11-03

Similar Documents

Publication Publication Date Title
WO2015154637A1 (en) Method for preparing silodosin intermediate
CN102639486B (en) Process for manufacture of N-acylbphenyl alanine
WO2016110224A1 (en) Preparation method for bemaciclib
EP3712130A1 (en) Method for synthesis of roxadustat and intermediate compounds thereof
CN102746210A (en) Synthesis method for key intermediate of silodosin
CN106977516B (en) A kind of preparation method of Tadalafei
KR20170131508A (en) METHOD FOR PREPARING LEDIPHASBIR AND ITS DERIVATIVES AND INTERMEDIATE COMPOUND FOR THE PREPARATION OF REDIPASVIR
CN103420893A (en) Method for preparing silodosin intermediate
JP2022508494A (en) Method for Producing Morpholine Quinazoline Compound and its Intermediate
CN112851646B (en) Preparation method of tergolian prazan
CN114315823B (en) Intermediate of berberine hydrochloride and analogues thereof and preparation method thereof
Wu et al. Cascade reaction of β, γ-unsaturated α-ketoesters with phenols in trityl chloride/TFA system. Highly selective synthesis of 4-aryl-2 H-chromenes and their applications
EP3601262B1 (en) Process for the preparation of a sulfonamide structured kinase inhibitor
WO2018205299A1 (en) 4,5-disubstituted-1-hydro-pyrrole(2,3-f)quinolone-2,7,9-tricarboxylate compound and applications
CN109384767B (en) Preparation method and intermediate of pyridopyrimidine derivative
CN108822112A (en) A kind of preparation method of tropsch imatinib compound
CN107935909B (en) Synthesis method of nintedanib and intermediate thereof
CN109020895B (en) Synthesis method of metal-catalyzed 1-benzylamino-substituted benzimidazole
WO2023020531A1 (en) Method for synthesizing 5,8-diamino-3,4-dihydro-2h-1-naphthalenone and intermediate compound used therein
CA2750125A1 (en) Methods for preparing s1p receptor agonists and antagonists
WO2020125581A1 (en) Amide derivatives and preparation method for intermediates thereof
WO2020181860A1 (en) Method for preparing rivaroxaban intermediate
CN111499575B (en) Method for preparing lorcaserin
US10836751B2 (en) Methods for preparing Nintedanib and intermediates thereof
CN112479876B (en) Oxazepane spiro compounds, intermediates and process for their preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15776596

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15776596

Country of ref document: EP

Kind code of ref document: A1